Aldose Reductase Inhibitor

CC13401 is an aldose reductase (ALR2) inhibitor with an IC₅₀ of 41.41 μM in rats. CC13401 inhibits the NADPH-dependent reduction reaction catalyzed by ALR2. CC13401 can be used in studies on the mechanisms related to the polyol pathway and diabetic complications.

Aldose reductase-IN-2 (Compound 5f) is a potent inhibitor of aldose reductase (AR). Aldose reductase-IN-2 has antioxidation capacity. Aldose reductase-IN-2 is a promising anti-diabetic complications agent.

CPSA is a potent and competitive inhibitor against 20α-hydroxysteroid dehydrogenase (AKR1C1) with a K_i value of 0.86 nM. CPSA is promising for research of lung and endometrial cancers, premature birth and neuronal disorders.

12-O-β-D-Glucopyranosyloxyjasmonic acid is a naturally occurring aldose reductase (ALR2) inhibitor found in Schizonepeta tenuifolia Briq. 12-O-β-D-Glucopyranosyloxyjasmonic acid is used in research related to aldose reductase-mediated diseases, such as diabetes.

ALR2-IN-2 is a potent inhibitor of aldose reductase (ALR2), with IC₅₀s of 27 nM and 228 nM for rat ALR2 and ALR1, respectively. ALR2-IN-2 can be used for the research of diabetic complications.

Aldose reductase-IN-3 (Compound 5) is a potent and moderately selective inhibitor of aldose reductase (AR) with an IC₅₀ of 3.99 μM. Aldose reductase has recently emerged as a molecular target that is involved in various inflammatory diseases, including sepsis. Aldose reductase-IN-3 has the potential for the research of sepsis.

M 16209 is an orally active aldose reductase (AR) inhibitor. M 16209 inhibits partially purified AR from various sources with IC₅₀ values of 0.12, 0.24, 4.5, 1.2 and 9.3 μM for rat lens AR, bovine lens AR, bovine kidney AR, canine lens AR and human placental AR. M 16209 can be used for the research of metabolic disease, such as diabetes.

6-Methoxytricin (Compound 6) is an flavonoid isolated from Artemisia iwayomogi. 6-Methoxytricin (Compound 6) is an inhibitor on aldose reductase (AR) and advanced glycation endproduct (AGE) formation activities with IC₅₀ values of 30.29 μM and 134.88 μM, respectively. 6-Methoxytricin (Compound 6) has potential as an anti-diabetic complications agent.

ADN-138 is an aldose reductase inhibitor. ADN-138 reduces sorbitol levels in diabetic nerves and results in significant increases in MNCV and Na⁺, K⁺-ATPase in the nerves. ADN-138 can be used in the research of diabetic nerve complications.

Hydroxyevodiamine inhibits aldose reductase with an IC₅₀ value of 24.1 μM.

EBPC is a potent and selective aldose reductase inhibitor with an IC₅₀ of 47 nM.

AZ-11665362 is a CRTh2 (DP2) receptor antagonist with an IC₅₀ of 2.6 nM. AZ-11665362 shows weak activity against aldose reductase, serotonin transporter, CYP 2C19, and CYP 2C9. AZ-11665362 lacks measurable inhibitory activity against COX-1 and COX-2. AZ-11665362 can be used for the research of asthma, and other inflammatory diseases.

6,7-Dihydroxy-4-coumarinylacetic acid is a potent and selective inhibitor of ALR2. 6,7-Dihydroxy-4-coumarinylacetic acid inhibits ALR2, SDH andALR1 with IC₅₀s of 9.6, 288 and 66.3 μM, respectively. 6,7-Dihydroxy-4-coumarinylacetic acid clearly suppresses galactitol accumulation.

(Rac)-Fidarestat ((Rac)-SNK 860) is the racemate of Fidarestat (HY-105185). (Rac)-Fidarestat is a potent aldose reductase inhibitor.

Aldose reductase-IN-10 is an inhibitor of aldose reductase with an IC₅₀ of 1.965 μM. Aldose reductase-IN-10 reduces malondialdehyde levels and enhances the activities of SOD, CAT and GPx. Aldose reductase-IN-10 decreases total cholesterol, triglyceride and LDL-C levels, while increasing HDL-C levels. Aldose reductase-IN-10 can be used for the research of diabetic complications.

ALR2/α-Glucosidase-IN-2 is an inhibitor of α-glucosidase and aldose reductase ALR2. ALR2/α-Glucosidase-IN-2 has a K_i value of 11.68 nM against yeast α-glucosidase and a K_i value of 72.64 nM against ovine ALR2. ALR2/α-Glucosidase-IN-2 inhibits intestinal carbohydrate digestion regulatory enzymes and key enzymes in the polyol pathway. ALR2/α-Glucosidase-IN-2 can be used in diabetes-related research.

FR-62765 is a derivative of WF-3681. FR-62765 can significantly inhibit the accumulation of sorbitol in the sciatic nerve and the decrease of motor nerve conduction velocity in the tail of diabetic neuropathy rats, which can be used in the research of diabetic neuropathy.

ARI-809 (CP-744809) is a highly selective, orally active aldose reductase inhibitor with an IC₅₀ of 1 nM. ARI-809 blocks excessive glucose flux through the polyol pathway. ARI-809 normalizes elevated sorbitol and fructose levels in sciatic nerve tissues of diabetic rat models, inhibits sorbitol accumulation in lens tissues, and brings elevated urinary albumin excretion close to normal. ARI-809 can be used in diabetes research.

Aldose reductase-IN-6 (Compound 3) is a competitive aldose reductase (AR) inhibitor with an IC₅₀ of 3.164 μM and a K_i of 0.018 μM. Aldose reductase-IN-6 exhibits no cytotoxicity against healthy cells.

SG-210 (SPR 210) is an orally active and selective aldose reductase (AR) inhibitor. SG-210 has IC₅₀ values of 9.5 nM and 10 nM for AR from porcine lens and human placenta, respectively. SG-210 can inhibit sorbitol accumulation and ameliorate diabetic neuropathy and retinopathy in Streptozotocin (HY-13753)-induced diabetic rats. SG-210 can be used in the research of diseases such as diabetes-related complications.